Search results
Showing: 10 of 329
Drug Tariff News – April Part VIIIA reimbursement prices
The Department of Health has agreed that the April Drug Tariff Part VIIIA reimbursement price for the following items will be:
Clindamycin 150mg capsules £4.85
Flecainide 50mg tablets £11.57
Leflunomide 20mg tablets £8.16
and not as printed in…
Drug Tariff Part VIIA: Quality Payments Scheme (England): Correction
Drug Tariff Part VIIA: Quality Payments Scheme (England): Correction
Contractors should be made aware that paragraph 2.1 of Part VIIA in the October Drug Tariff should read:
“There will be one review on 15 February 2019, at which quality payments…
Community Pharmacy Contractual Framework (CPCF) 2018/19 funding
The Department of Health and Social Care with the Pharmaceutical Services Negotiating Committee’s agreement is maintaining CPCF funding for 2018/19 at the same level as last year, i.e. £2.592 billion. In order to deliver this level of funding the…
Manufacturers and suppliers
Guidance for manufacturers and suppliers of medicines, oxygen and appliances.
This includes:
updating us on product details and price information through Medicines Data - dm+d
access to the home oxygen therapy application
information on…
Pharmaceutical form refer backs
We have recently noticed a rise in items that are being referred back to contractors for the reason code RB2B: ‘The order/endorsement is incomplete. The presentation must be present.’ This commonly occurs with handwritten prescriptions.
If you…
Drug Reimbursement – Azathioprine 50mg/5ml oral suspension
Since February 2024, a licensed version of Azathioprine 50mg/5ml oral suspension became available. Therefore, for prescriptions dispensed in February and March 2024:
where there is an endorsement for the licensed product, then reimbursement will…
Migration of reports from Information Services Portal (ISP) to ePACT2 and Catalyst
We're currently working to migrate a number of reports from ISP to ePACT2 and the new public facing portal ‘Catalyst’.
We're removing access to a number of reports currently viewed via ISP on Friday 11 January 2019 in preparation of the migration…
Endorsing correctly in EPS: actual medicinal product pack
We have received a number of enquiries from contractors who have endorsed an incorrect product and pack size, leading to referred backs and delays in payment.
When dispensing a drug not listed in Part VIII of the Drug Tariff, you must endorse…
2022 PhAS Review – application window
The 2022 PhAS started on 1 January 2022 with payments for the 2022 PhAS made with the reconciliation payment from 1 April 2022.
Contractors can apply for review of their PhAS eligibility as set out in the Pharmacy Access Scheme guidance. The review…
Raising dm+d issues
Do not use the contact details on this page for routine enquiries
For initial and routine enquiries, email us at dmdenquiries@nhsbsa.nhs.uk, or use the specific email addresses listed under the Contact us section of the dm+d homepage.
You…